CDK2 and cancer: It appears that silibinin was also able to decrease the kinase activities of Cdk2 and 4 and at the inverse to increase Cdk inhibitors that control negatively Cdk-cyclin complexes such as Kip1/p27, Cip1/p21 and p18/INK4C in in vitro and in vivo in various cancers [47,48,49,50,51,52,54,55,56,57,64,65].